<DOC>
	<DOCNO>NCT01801358</DOCNO>
	<brief_summary>A phase Ib dose-escalation study AEB071 MEK162 combination adult patient confirm metastatic uveal melanoma . Cohorts 3-6 patient assess dose limit toxicity ( DLTs ) Cycle 1 maximum tolerate dose ( MTD ) combination therapy determine . The MTD Phase 2 Recommended Dose ( P2RD ) use Phase II part study , enrol 55 patient two randomized group : combination therapy MEK162 alone . The Phase II part continue proof concept establish . Patients continue treatment long clinical benefit see limit adverse toxicity observe</brief_summary>
	<brief_title>A Phase Ib/II Study AEB071 MEK162 Adult Patients With Metastatic Uveal Melanoma</brief_title>
	<detailed_description>Due halt enrollment , Phase II part study conduct . The Sponsor decide permanently stop recruitment study prior MTD determination . Remaining patient treatment binimetinib sotrastaurin consider Investigator benefit treatment could continue treatment follow per protocol . No patient ongoing data cut-off date . After last patient last visit ( LPLV ) declare , study terminate .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>Written inform consent Male female patient age 18 year old A history uveal ( ocular ) melanoma biopsyconfirmed metastatic disease Consent provide 3 tumor biopsy sample throughout course study Presence measurable disease A WHO performance status less equal 1 Presence CNS lesion ( stable lesion may acceptable ) Previous concurrent malignancy , basal cell squamous cell carcinoma skin : situ carcinoma cervix , without evidence recurrence least 3 year ; primary malignancy completely resect evidence recurrence least 3 year Adverse event prior chemotherapy , radiotherapy surgery recover CTCAE v4.03 Grade 1 less , except alopecia/sensory peripheral neuropathy , must less Grade 2 History current evidence retinal vein occlusion ( RVO ) current risk factor RVO Impaired cardiac function clinically significant cardiac disease Impaired GI function disease could interfere absorption AEB071 and/or MEK162 Treatment medicine herbal supplement know inhibitor inducer CYP3A4/5 withdrawn prior study treatment Females childbearing potential unwilling unable use highly effective mean contraception Males unwilling unable use condom sexual intercourse Prior exposure MEK PKC inhibitor Other inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Melanoma ,</keyword>
	<keyword>melanoma eye ,</keyword>
	<keyword>uveal ,</keyword>
	<keyword>MEK162 ,</keyword>
	<keyword>AEB071</keyword>
</DOC>